Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Angiocrine Bioscience, Inc. logo — Transforming medicine through engineered cellular therapies...

Angiocrine Bioscience, Inc.

Transforming medicine through engineered cellular therapies that restore, regenerate, and repair tissues and organs.

Founded 2012 United States San Diego, United States 21 employees Grant Total: $77.12M Biotechnology, Health Care +1

General Information

Company Name Angiocrine Bioscience, Inc.
Founded Year 2012
Location United States San Diego, United States
Founders / Decision Makers
Team member
Employees 21
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Angiocrine Bioscience, Inc.. To contact Angiocrine Bioscience, Inc., visit angiocrinebioscience.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Angiocrine Bioscience, Inc. compare?

A PDF of Angiocrine Bioscience, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Angiocrine Bioscience, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Angiocrine Bioscience, Inc.

Angiocrine Bioscience, Inc. is a private, clinical stage engineered cell therapy company that aims to transform medicine through engineered cellular therapies that restore, regenerate, and repair tissues and organs. Founded in 2012 and headquartered in the United States, the company is focused on harnessing the power of genetically modified human endothelial cells to address serious medical conditions.

The company's proprietary engineered endothelial cell (E-CEL®) therapies have garnered attention for their potential to treat multiple life-threatening hemato-oncologic and immunologic conditions, as well as regenerate tissues and organs affected by diseases. At 19 December 2022, Angiocrine Bioscience secured a significant $15.00M grant investment from the California Institute for Regenerative Medicine.

Angiocrine Bioscience operates within the Biotechnology and Health Care industries, positioning itself at the forefront of innovative medical advancements. With a focus on cellular therapies, the company holds promise for disrupting traditional medical treatments and offering new possibilities for patients with serious medical conditions.

Business keywords: cell therapy, genetically modified cells, regenerative medicine, endothelial cells, clinical stage, hemato-oncologic conditions, immunologic conditions, vascular niche, stem cell therapy, progenitor cells, organ regeneration, gene therapy, immunotherapy, engineered cellular therapies, tissue engineering

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $15.00M 1
California Institute for Regenerative Medicine
19 Dec 2022
Private Equity Round $58.12M -
15 Oct 2021
Venture Round $4.00M 1
Gutbrain Ventures
Gutbrain Ventures
13 Mar 2013

Angiocrine Bioscience, Inc. Alternatives & Competitors

View All Alternatives
Angiocrine Bioscience, Inc. vs
Harvard Apparatus Regenerative Technology, Inc.
Harvard Apparatus Regenerative Technology, Inc. United States

HRGN is a bioengineering company that is developing next-generation esophageal implants.

Post-IPO Equity
13 employees
Biotechnology, Health Care
Angiocrine Bioscience, Inc. vs
Bonus Biogroup
Bonus Biogroup Israel

Innovation ★ Tissue Engineering ★ Cell Therapy ★ Impact

47 employees
Biotechnology, Health Care
Angiocrine Bioscience, Inc. vs
Stembio Cell and Tissue Technologies Inc.
Stembio Cell and Tissue Technologies Inc. Turkey

Our purpose is to build a leading, focused ATMPs company powered by advanced therapy platforms and d...

89 employees
Biotechnology, Health Care
Also compare with: Angiocrine Bioscience, Inc. vs Sana Biotechnology, Inc. Sana Biotechnology, Inc. View all alternatives

FAQ About Angiocrine Bioscience, Inc.

Transforming medicine through engineered cellular therapies that restore, regenerate, and repair tissues and organs.
Angiocrine Bioscience, Inc. was founded in 2012.
Angiocrine Bioscience, Inc. is headquartered in San Diego, United States.
Angiocrine Bioscience, Inc. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on cell therapy, genetically modified cells, regenerative medicine and endothelial cells.
Angiocrine Bioscience, Inc. has approximately 21 employees.
Angiocrine Bioscience, Inc. has completed 3 funding rounds, raising a total of $77.12M. The latest funding stage is Grant.
Top alternatives and competitors to Angiocrine Bioscience, Inc. include Harvard Apparatus Regenerative Technology, Inc., Bonus Biogroup, Stembio Cell and Tissue Technologies Inc., StemSight - Vision Unlimited, Minerva Biotechnologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Angiocrine Bioscience, Inc. and Harvard Apparatus Regenerative Technology, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Angiocrine Bioscience, Inc., https://bouncewatch.com/company/angiocrine-bioscience-inc, updated 5 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout